MCH ANALYSIS RESEARCHMain site ↗
Real Estate

Health Care REITs

8 companies under coverage.

Coverage

Health Care REITs


Equity Research

Healthcare Realty Trust Incorporated (HR)

BUY. 12-month probability-weighted target $21 (+23% vs spot). P/E Multiple explains 74% of Monte Carlo outcome variance.

HREquity ResearchMonte Carlo
10 October 2026Rating: BUY · Fair value vs price +18.8%
Equity Research

CareTrust REIT Inc. (CTRE)

HOLD. 12-month probability-weighted target $42 (+16% vs spot). P/E Multiple explains 94% of Monte Carlo outcome variance.

CTREEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +13.3%
Equity Research

Ventas Inc (VTR)

HOLD. 12-month probability-weighted target $92 (+12% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

VTREquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +6.9%
Equity Research

Healthpeak Properties Inc (DOC)

HOLD. 12-month probability-weighted target $21 (+10% vs spot). P/E Multiple explains 83% of Monte Carlo outcome variance.

DOCEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +6.2%
Equity Research

Welltower Inc (WELL)

HOLD. 12-month probability-weighted target $241 (+7% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

WELLEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +5.4%
Equity Research

Sabra Healthcare REIT Inc (SBRA)

HOLD. 12-month probability-weighted target $20 (+3% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.

SBRAEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -0.4%
Equity Research

American Healthcare REIT, Inc. (AHR)

HOLD. 12-month probability-weighted target $47 (-8% vs spot). Gross Margin explains 56% of Monte Carlo outcome variance.

AHREquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -11.3%
Equity Research

Omega Healthcare Investors Inc (OHI)

Rating suspended since 2026-10-02 — under analyst review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

OHIEquity ResearchMonte Carlo
2 October 2026Rating: N/A
MCH ANALYSIS · All research · Research, not personal financial advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.20.0 · US-listed

MCH Analysis is a general investment-research publication of MCH Advisory (Pty) Ltd. It is not personal financial advice and does not take your circumstances into account. MCH is not a licensed financial services provider or a registered investment adviser. Past performance, whether actual or simulated, does not predict future results. Subscriber Agreement | Privacy and Cookie Notice | Research Governance Policies